Page Title

VPM helps facilitate fast track designation for Memo Therapeutics AG’s AntiBKV first-in-class treatment for BK virus infection in renal transplant recipients

Vakzine Projekt Management GmbH (VPM) announced today that it has supported Memo Therapeutics AG (MTx) during the process for receiving fast track designation from the U.S. Food and Drug Administration (FDA) for the novel human monoclonal antibody, AntiBKV, developed by MTx for the treatment of BK viremia in kidney transplant recipients.  READ MORE.